Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 9/20 | 0.56 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23454374 | 0.91 | CYP1A2 (0.55) | CYP1A2SCN5ADGAT1AAK1PIK3CA | |
| SCHEMBL23116252 | 0.90 | CYP1A2 (0.58) | CYP1A2SCN5ADGAT1AAK1RIPK1 | |
| SCHEMBL29900839 | 0.90 | CYP1A2 (0.58) | CYP1A2SCN5ADGAT1AAK1RIPK1 | |
| SCHEMBL20204062 | 0.90 | CYP1A2 (0.66) | CYP1A2SCN5ADGAT1 | |
| Relutrigine SCHEMBL23132181 | 0.90 | CYP1A2 (0.54) | CYP1A2SCN5ADGAT1AAK1 | |
| SCHEMBL26539162 | 0.89 | CYP1A2 (0.57) | CYP1A2SCN5ADGAT1AAK1 | |
| SCHEMBL23115992 | 0.88 | CYP1A2 (0.55) | CYP1A2SCN5ADGAT1AAK1 | |
| SCHEMBL23116139 | 0.87 | CYP1A2 (0.57) | CYP1A2SCN5ADGAT1AAK1 | |
| SCHEMBL23116012 | 0.87 | CYP1A2 (0.60) | CYP1A2SCN5ADGAT1 | |
| SCHEMBL23116160 | 0.86 | CYP1A2 (0.52) | CYP1A2SCN5ADGAT1AAK1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376475-A1 | ION CHANNEL MODULATORS | PRAXIS PREC MEDICINES INC (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4487916-A2 | ION CHANNEL MODULATORS | Praxis Precision Medicines, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240132501-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-04-25 | — | — | US | disclosed |
| US-11866439-B2 | Ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-11731978-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731978-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731978-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731976-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731976-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731976-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20220220118-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2022-07-14 | — | — | US | disclosed |
| US-20220024930-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20220024930-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20210163488-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-06-03 | — | — | US | disclosed |
| US-20210163488-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-06-03 | — | — | US | disclosed |
| US-11014931-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyrazine as an ion channel modulator | PRAXIS PRECISION MEDICINES, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-11014931-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyrazine as an ion channel modulator | PRAXIS PRECISION MEDICINES, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3801535-A1 | ION CHANNEL MODULATORS | Praxis Precision Medicines, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20210087197-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-03-25 | — | — | US | disclosed |
| US-20210087197-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731978-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator | SCN1A, SCN3A, CACNA1F | CYP1A2 3672/4885SCN5A 8/4885DGAT1 1960/4885 |
| US-20240132501-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | CYP1A2 2873/4885SCN5A 5/4885DGAT1 596/4885 |
| US-20220220118-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | CYP1A2 2873/4885SCN5A 5/4885DGAT1 596/4885 |
| US-20210087197-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | CYP1A2 2873/4885SCN5A 5/4885DGAT1 596/4885 |
| US-11731976-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator | SCN1A, SCN3A, CACNA1F | CYP1A2 3699/4885SCN5A 8/4885DGAT1 2062/4885 |
| US-11866439-B2 | Ion channel modulators | SCN1A, SCN3A, SCN2A | CYP1A2 2873/4885SCN5A 5/4885DGAT1 596/4885 |
| US-20210163488-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | CYP1A2 2873/4885SCN5A 5/4885DGAT1 596/4885 |
| US-20220024930-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | CYP1A2 2873/4885SCN5A 5/4885DGAT1 596/4885 |
| US-11014931-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyrazine as an ion channel modulator | SCN3A, SCN1A, SCN5A | CYP1A2 2631/4885SCN5A 3/4885DGAT1 1531/4885 |
| US-20250376475-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | CYP1A2 2873/4885SCN5A 5/4885DGAT1 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.